Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shekhar Ghamande

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
MMWR. Morbidity and Mortality Weekly Report|March 24, 2022
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022Mark W Tenforde, Wesley H Self, Manjusha Gaglani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2021
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024Kevin C Ma, Diya Surie, Adam S Lauring, et al.
MMWR. Morbidity and Mortality Weekly Report|September 23, 2021
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021Wesley H Self, Mark W Tenforde, Jillian P Rhoads, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
MMWR. Morbidity and Mortality Weekly Report|March 24, 2022
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022Mark W Tenforde, Wesley H Self, Manjusha Gaglani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2021
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024Kevin C Ma, Diya Surie, Adam S Lauring, et al.
MMWR. Morbidity and Mortality Weekly Report|September 23, 2021
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021Wesley H Self, Mark W Tenforde, Jillian P Rhoads, et al.
Pageof 9